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have normal quantitative expression of glycoprotein 
Ib-IX-V complex. However, the glycoprotein can 
be functionally defective and therefore displays an 
identical phenotype to the classical form of the 
disease. 
It is essential to maintain a broad differential 
diagnosis, especially when the clinical presentation is 
unusual, and does not respond to conventional thera­
pies. Our ﬁndings demonstrate that, in cases of 
macrothrombocytopenia, reduced ristocetin-induced 
platelet aggregation may be sufﬁcient for a diagnosis 
of Bernard–Soulier syndrome to be made even in the 
absence of a reduction in glycoprotein expression. 
The vast amount of SNP data, generated by genome 
projects will increasingly present interpretive chal­
lenges in assessing the variants of unknown clinical 
signiﬁcance in speciﬁc patient populations. Further, 
the curation of SNP and locus speciﬁc mutation data­
bases does not always favour the distinction between 
pathogenic and benign variants: In Bernard–Soulier 
syndrome, as in other autosomal recessive disorders, 
the report of a small number of heterozygous individ­
uals should not preclude the variant from being con­
sidered potentially pathogenic in the homozygous 
state. 
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The treatment paradigm for bleeding management in the clotting defect. For the management of patients 
patients with congenital bleeding disorders is Replace- with factor VII (FVII) deﬁciency, a rare bleeding dis­
ment Therapy (RT), based on the substitution of the order, a number of therapies are available, including 
missing coagulation factor, with the aim of correcting plasma or plasma-derived products as well as recom­
binant products [1,2]. However, information regard-
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It is taken for granted that all RT types and 
schedules are associated with potential side-effects, 
and there is no doubt that the management of 
patients with bleeding disorders can be improved by 
reducing the occurrence of AEs and their severity. 
Awareness of AEs is indeed a relevant issue in the 
management of rare bleeding disorders, where data 
collection, especially in a prospective fashion, is very 
difﬁcult. 
The Seven Treatment Evaluation Registry (STER) 
has prospectively collected a large amount of informa­
tion on the management of patients with congenital 
FVII deﬁciency [9–13]. The aim of this study was the 
systematic analysis of AEs related to treatments, for 
prophylaxis [9], surgical interventions [10,12] and 
spontaneous or traumatic bleeding episodes [11]. 
Patients with congenital FVII deﬁciency managed 
for a large array of clinical indications were investi­
gated for RT-related AEs during the 8-year duration 
of the STER (deadlock date: February 28th, 2012). 
STER was a prospective, observational, multicentre, 
web-based registry created to collect and describe data 
on treatment modalities and outcomes in patients with 
this rare bleeding disorder. All treatment procedures 
were in accordance with the ethical standards and 
approved by the Ethics Committee of L’Aquila 
University Hospital (coordinator’s institution) and the 
committees of all the other enrolling centres. Decisions 
on type of RT and schedules were autonomously 
taken by enrolling physicians. 
Because of different viral ecologies, treatment atti­
tudes and laboratory issues, pharmacovigilance was 
limited to non-blood-borne virus-related AEs; deci­
sions on RT type and schedules were taken autono­
mously by the enrolling physicians. The STER study 
protocol was designed to capture the following ele­
ments related to AEs: clinical description, evaluation 
of severity (serious or non-serious), potential associa­
tion with type of treatment (likely or unlikely) and 
outcome (including mortality for any reason). Throm­
bosis diagnosis (venous or arterial) was based on clini­
cal suspicion and conﬁrmed by imaging. FVII: c was 
determined at baseline and 15 min after the ﬁrst RT 
administration for the treatment reported. STER pro­
tocol was designed to centrally determine inhibitors at 
the following time points: ﬁrst enrolment (before RT 
administration), 30 days follow-up after the reported 
RT and when needed for clinical suspicion. Screening 
for inhibitory antibodies to FVII was conducted in a 
centralized fashion [4,13]; only baseline samples with 
FVII:c <4% were considered for inhibitor assay. 
Enrolling physicians were asked to carefully describe 
the type of AE, timing of occurrence after RT, clinical 
management and outcome. AEs were evaluated at the 
time of treatment and at the 30-day follow-up visit 
(or later if needed). Data were obtained from the 
STER database and analysed following a data quality 
and consistency check according to the STER data-
management plan. We calculated the cumulative inci­
dence rate of AEs in our cohort as the number of new 
cases per population at risk in a 8 years observational 
period and the incidence density rate (or person-time 
incidence rate) as number of new cases per population 
at risk in a given time period when the denominator is 
the sum of the person-time of the at risk population. 
With regard to every type of AE, we also calculated 
the prevalence in our cohort for speciﬁc adverse events 
as the proportion of cases in the population at the end 
of the study. Analyses were performed using the MEDI­
®
CAL software version 7.4.1.2 (http: www.med­
calc.org). We here focus on inhibitor development and 
thrombosis, being these considered the most relevant 
AEs related to RT. Other side-effects reported after 
RT (n = 11) consisted mainly in re-bleeding (n = 4) 
and aspeciﬁc symptoms like headache, virosis and 
fever, judged as unlikely related to RT (n = 7). STER 
overall enrolled 225 patients with congenital FVII 
deﬁciency and a total of 312 treatments were adminis­
tered: recombinant activated FVII (rFVIIa, Novo 
Seven®, Novo Nordisk A/S, Denmark, n = 245 
[78.5% of all replacement therapies]); plasma-derived 
FVII concentrates (pd-FVII, Facteur VIITM LFB, Cour­
taboef, France or Provertin-UM TIM3TM, Baxter, 
Vienna, Austria; FVII NF, Baxter, n = 31, 9.9%); 
Fresh Frozen Plasma (FFP), n = 30, 9.6%); Prothrom­
bin Complex Concentrate (PCC, Prothromplex TIM 
3, Baxter; Prothromplex Total TIM 4, Baxter, n = 5, 
1.6%), and in one case FEIBA (Baxter). The AE’s 
cumulative incidence was (2.2%, CI 0.6–3.9%) and 
the incidence density rate was 1.6% (CI 0.0–2.5%) 
per year. As for FVII inhibitors, 115 patients were 
centrally tested using a standardized modiﬁcation in 
the Bethesda assay. Inhibitors occurred in two of those 
patients in whom a centralized screening could be 
done (n = 125); two other inhibitor patients were 
enrolled in the STER but inhibitor could not be cen­
trally conﬁrmed for logistical reasons. Three of the 
four reported inhibitors were detected during prophy­
laxis with rFVIIa, in two young boys at the age of 
5 years and 1 year, respectively, and in one infant (a 
5 months old male). 
All cases had a very severe bleeding phenotype 
(epistaxis, easy bruising, gastrointestinal bleeding, 
CNS bleeding, subcutaneous and muscle haematoma). 
Baseline FVII:c levels were 2, 1.3 and <1% respec­
tively. All the three patients were previously exposed 
to multiple FFP infusions and prophylaxis with 
rFVIIa was instituted to prevent CNS (in two cases) 
and GI (in one case) bleedings. The immune response 
in FVII deﬁciency was not complicated by anaphylac­
tic reactions. Prophylaxis was continued in all three 
patients without any safety problem or reported dose-
adjustment. All the patients were high responders 
with peak titres of between 34 and 68.3 BU mL-1 
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Table 1. Thrombosis and inhibitors reported to the STER. 
Replacement FVII:c Severity/Relation 
Sex/Age therapy FVII:c(%) 00 (%) 150 Clinical setting Event Timing to replacement 
Thrombosis 
M/8 rFVIIa 15 lg 
Kg -1 9 43, 
2.3 320 Neurosurgery Cerebral infarct 8th day Serious/Likely 
FFP 10 IU 9 13 
M/23 rFVIIa 30 lg 
Kg -1 9 3 
6 99 Orthopaedic 
surgery 
SVT 1st day Non-serious/ 
Likely 
M/53 rFVIIa 30 lg 
kg -1 9 2, 22.5 lg 
kg -1 9 1, 15 lg 
kg -1 9 28 
4.8 380 Renal transplant Stroke 30 days Serious/Likely 
Inhibitors 
F/53* 
(p.A354V; p.464Hfs) 
M/5* (p.Ser112 Stop) 
M/0.5 
M/1 
rFVIIa†,‡ 30 lg 
Kg -1 9 1, 10 lg 
Kg -1 9 8 
rFVIIa†,‡ 30 lg 
Kg -1 9 21 days 
rFVIIa†,‡ 65 lg 
Kg -1 9 1/week 
rFVIIa†,‡ 31 lg 
Kg -1 9 3/week 
<1§ 
2§ 
1.3§ 
<1§ 
/ 
/ 
/ 
/ 
Minor surgery 
Prophylaxis for 
CNS bleeding 
Prophylaxis for 
CNS bleeding 
Prophylaxis for 
GI bleeding 
High titre10–20 BU 
High titre 38-68.3 BU 
High titre 5.5-60 BU 
High titre 32–72 BU 
Postoperatively 
3 months¶ 
5 months¶ 
1 month¶ 
Serious/Likely§ 
Serious/Likely 
Serious/Likely 
Serious/Likely 
Brackets report FVII gene mutation, SVT, superﬁcial vein thrombosis. Age is expressed in years. 
*inh. detected centrally. 
†Schedule refers to RT prior to inhibitor(inh). detection. 
‡All patients received different treatments (pdFVII, FFP) before inh. detection. 
§Baseline levels. 
¶Age at inhibitor screening. 
BU=Bethesda Units. 
(Table 1) at the last available follow-up (1 month 
after detection). 
One case of inhibitor was detected in adulthood, in 
a 53 year-old woman previously treated with FFP, pd-
FVII and PCC for recurrent bleeding episodes (mainly 
gynaecological). Inhibitor was discovered when the 
patient underwent multiple dental extractions, the 
patient was treated with rFVIIa given at an initial 
dose of 30 lg kg  -1 followed by eight consecutive 
boluses of 10 lg Kg  -1. Patients were not reported to 
undergo any speciﬁc treatment for inhibitor eradica­
tion (Table 1). 
Thrombosis occurred in three patients: two cerebral 
infarctions and one superﬁcial vein thrombosis (1% of 
treatments). Dosing and treatment schedules are 
shown in the Table 1. 
In the ﬁrst case (M/8), treated for the evacuation of 
left cerebellar haematoma, RT with rFVIIa lasted 
8 days; rFVIIa was administered immediately before 
the procedure and for the following 7 days at a dose 
of 18 lg Kg  -1 every 6 h. FFP was than administered 
up to 16 days post procedure at a dose of 10 U Kg -1, 
every 6 h. 
In the second case (M/23), treated for knee replace­
ment, RT with rFVIIa was given before the proce­
dure and every 12 h in the following 24 h after 
orthopaedic surgery at a dose of 30 lg Kg  -1. Superﬁ­
cial Vein Thrombosis (SVT), conﬁrmed with Doppler 
ultrasounds, involved the cephalic vein of the right 
arm. 
In the third case (M/53), treated for kidney trans­
plant, rFVIIa was administered 30 min before the pro­
cedure and 15 min thereafter. After 1 h, the dose of 
rFVIIa was empirically lowered to 22.5 lg kg  -1; after 
4 h, rFVIIa was given at 15 lg kg  -1. The following 
RT administrations occurred at 8, 18, 24 and 30 h 
after the ﬁrst one, namely at a doses of 15 lg kg  -1. 
Starting from 36 h, rFVIIa (15 lg kg  -1) was adminis­
tered every 6 h until 96 h (day 4), when the same 
dose was injected twice a day for the following 
6 days. The patient was discharged under immunosup­
pressive drugs. At 30 days follow-up visit he presented 
with a paralysis of the right leg started 48 h before 
admission, a CT scan conﬁrmed the involvement of 
the left anterior cerebral artery and the patient was 
treated with Low Molecular Weight Heparin 
(LMWH) at prophylactic dose for 2 weeks, without 
any bleeding complication and a partial relief of paral­
ysis. Further RT was not administered during 
LMWH. 
Inhibitors to FVII were considered the most impor­
tant side-effect associated with RT; we, therefore, per­
formed a screening using a standardized modiﬁcation 
in the Bethesda assay in a centralized fashion [4,6,13]. 
Of the two inhibitors screened and conﬁrmed by the 
Central Laboratory, one had been previously detected; 
one was a de novo event. FVII gene mutation is avail­
able only for two patients with inhibitors (one with a 
missense mutation plus one codon deletion and 
another homozygous for a nonsense mutation). 
© 2015 John Wiley & Sons Ltd Haemophilia (2015), 21, e479--e525 
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Inhibitor occurrence in FVII deﬁciency can be con­
sidered at least as rare as that currently reported in 
haemophilia B [6], where a prevalence of 2–3% is 
accepted. Comparison to FIX deﬁciency is the most 
reasonable one, due to a high comparability in the 
gene and protein structures of FIX and FVII, even 
though severe gene defects, such as large deletions, 
have not been reported in patients with FVII deﬁ­
ciency [14]. Another substantial difference between 
the two bleeding disorders is the occurrence of ana­
phylactic reactions, a severe clinical issue in patients 
with haemophilia B, that is absent in patients with 
inhibitors to FVII, as conﬁrmed by the fact that pro­
phylaxis in FVII-deﬁcient patients, can be continued 
even in the presence of an inhibitor [13]. Two other 
cases of inhibitor were reported in the STER but inhi­
bitor detection could not be determined in a central­
ized fashion. Considering the total number of patients 
enrolled in the STER (n = 225), the prevalence (1.8%) 
appears unchanged. 
The prevalence rate of thrombosis in the STER was 
1% (3/312 treatments). This prevalence is the same as 
that found in a retrospective study by our group [5]. 
Postinfusion FVII coagulant activity levels did not 
differ between those patients experiencing AEs and 
the other uncomplicated treatments (data not shown), 
and no relationship could be established between 
thrombosis occurrence and the dose of rFVIIa or 
patient’ age. The association between gene mutations 
and the risk of thrombosis has been explored [5] but 
even if two common mutations (Arg364Gln and 
Ala354Val) have been frequently detected in patients 
with thrombosis, no speciﬁc association has been 
found [5]. Thrombophilias, such as FV Leiden, pro­
thrombin gene mutation, antiphospholipid antibodies 
syndrome and elevated clotting FVIII levels, were pre­
sent in some cases of FVII deﬁciency with thrombosis, 
but they did not seem to play a relevant role as risk 
factors for thrombosis, since thrombophilia markers 
appeared to have a similar prevalence in patients with 
and without thrombotic complications [5]. This study 
suggests that FVII deﬁciency does not provide protec­
tion from thromboembolism, either arterial or venous, 
especially in a surgical setting. The indication for 
thromboprophylaxis in high-risk patients (e.g. patients 
congenital References of factor 
undergoing major surgery and high-dose RT) still 
needs to be formally evaluated, but anecdotal reports 
suggest that it does not increase the risk of bleeding 
[5]. 
An important issue regards the frequency of surgery 
as a clinical setting associated with AEs, at least in 
this report (57.1%). Considering the reported AEs and 
the other side-effects (n = 11, data not shown), surgi­
cal interventions appear to play a not negligible role 
in the occurrence of adverse events (RR 2.5, 
P = 0.0574, CI 0.97–6.54). 
This study focusing on AEs checked prospectively in 
a large number of patients with FVII deﬁciency and 
over a large array of clinical settings highlights a low-
to-very-low incidence of AEs. This indicates a very 
good safety-to-efﬁcacy ratio, especially for rFVIIa, the 
most used replacement treatment. 
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Compartment syndrome is a surgical emergency 
caused by an intrinsic or extrinsic event leading to an 
increased tissue pressure within a closed fascial com­
partment. Once this exceeds perfusion pressure a num­
ber of serious complications can occur with 
microvascular compromise and eventual tissue necro­
sis. Whilst the vast majority of cases of compartment 
syndrome result from fractures secondary to trauma, 
individuals with haemophilia present a unique group 
of patients at risk of spontaneous bleeding into a fas­
cial compartment or joint [1]. We present a case of 
atraumatic bilateral compartment syndrome of the 
forearms in a 21-year-old male with severe haemophi­
lia A and a FVIII inhibitor. 
A 21-year-old man with a background of severe 
congenital haemophilia A was admitted with pain and 
swelling of his left forearm. He had had a recent brief 
admission with a left shoulder haemarthrosis which 
was treated with rFVIII. Clinical response was poor 
and reduced FVIII half-life was demonstrated follow­
ing which the presence of a factor VIII inhibitor, with 
a titre of 1.0 BU mL -1, was conﬁrmed. Treatment 
with recombinant factor VIIa (rFVIIa, NovoSeven®; 
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Novo Nordisk A/S, Bagsværd, Denmark) was com­
menced. He had no other signiﬁcant past medical his­
tory. There was no history of direct trauma, although 
he had been attending the gym daily over a 2-month 
time period for weights training and body building. 
He admitted using protein shakes, purchased over the 
internet, but denied use of anabolic steroids. A rapid 
increase in his upper body muscle bulk had been 
recently noted by the haemophilia physiotherapist. 
On admission, he was haemodynamically stable but 
had pain on wrist and ﬁnger ﬂexion and an area of 
erythema around a previous cannulation site on the 
medial aspect of his left forearm. He was treated with 
intravenous antibiotics for cellulitis and rFVIIa for 
possible haematoma. An ultrasound scan performed to 
investigate progressive forearm swelling identiﬁed 
external cephalic vein thrombosis but no evidence of 
haematoma. Despite ongoing treatment, the symptoms 
progressed and pain became uncontrollable with opi­
ate analgesia. Active ﬁnger movements became impos­
sible. Passive extension caused severe pain and the 
forearm muscle bellies were exquisitely tender. How­
ever, radial and ulnar pulses were present and sensa­
tion was intact. A clinical diagnosis of compartment 
syndrome was made by the orthopaedic team and the 
patient was taken to theatre for urgent left forearm 
superﬁcial and deep ﬂexor compartment decompres­
sion. Compartment pressures were not measured. The 
muscles of the forearm were found to be grossly swol­
len with evident intramuscular bleeding, but no focal 
haematoma. Tissue necrosis was not evident at the 
DOI: 10.1111/hae.12783 
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